Cargando…

The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study

OBJECTIVE: Whether long-acting injectable antipsychotics (LAI) are superior to oral antipsychotics remains a controversial question, and results vary depending on the study design. Our study was performed to compare outcomes of oral anti-psychotics and paliperidone palmitate (PP) in clinical practic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, So-Young, Jon, Duk-In, Hong, Hyun Ju, Hong, Narei, Yi, Jung-Seo, Roh, Daeyoung, Jung, Myung Hun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852671/ https://www.ncbi.nlm.nih.gov/pubmed/31671491 http://dx.doi.org/10.9758/cpn.2019.17.4.531

Ejemplares similares

T201. EFFECTS OF PALIPERIDONE PALMITATE ON HEALTHCARE UTILIZATION AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA: A CLAIM-BASED MIRROR-IMAGE STUDY IN SOUTH KOREA
por: Hun Jung, Myung, et al.
Publicado: (2020)

Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea
por: Lee, Dasom, et al.
Publicado: (2020)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
por: Oh, Jihoon, et al.
Publicado: (2023)

Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
por: Bioque, Miquel, et al.
Publicado: (2020)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
por: Luo, Rui, et al.
Publicado: (2023)

T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
por: Ju Lee, Bong, et al.
Publicado: (2020)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study
por: Mahabaleshwarkar, Rohan, et al.
Publicado: (2021)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates
por: Bressington, Daniel, et al.
Publicado: (2015)

Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia
por: Zhang, Hongyan, et al.
Publicado: (2017)

Clinical experiences with 6-monthly paliperidone palmitate beyond the diagnosis of schizophrenia. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
por: Markovic, M.
Publicado: (2022)

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study
por: Pappa, Sofia, et al.
Publicado: (2020)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

A Case of Ileus in a Patient with Schizophrenia Under Paliperidone Palmitate Treatment
por: Can, Serdar Süleyman, et al.
Publicado: (2016)

Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
por: Bell Lynum, Karimah S., et al.
Publicado: (2018)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Different onset patterns of monthly paliperidone palmitate in hospitalised patient diagnosed with schizophrenia
por: Herrera-Sánchez, Javier, et al.
Publicado: (2021)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis—A Retrospective Mirror-Image Study
por: Chan, Chun Ting, et al.
Publicado: (2023)

A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
por: Liu, Jie, et al.
Publicado: (2022)

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
por: Hargarter, L, et al.
Publicado: (2016)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada, Ryohei, et al.
Publicado: (2018)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez, Alicia, et al.
Publicado: (2019)

M217. EFFICACY OF PALIPERIDONE PALMITATE ON PSYCHIATRIC SYMPTOMS AND ATTITUDES TOWARD MEDICATION IN SCHIZOPHRENIA
Publicado: (2020)

Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia
por: Elsisi, Gihan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_331ni9lc00fcl77j480j2iqpja